<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369092">
  <stage>Registered</stage>
  <submitdate>31/08/2015</submitdate>
  <approvaldate>2/02/2016</approvaldate>
  <actrnumber>ACTRN12616000114448</actrnumber>
  <trial_identification>
    <studytitle>a study for dosage of Andriol Testocaps in treatment of late-onset hypogonadism</studytitle>
    <scientifictitle>differential dosage of Andriol Testocaps in treatment of Chinese patients with late-onset hypogonadism</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>late-onset hypogonadism</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>lower dosage of Testosterone Undecanoate Capsule (Andriol) as two groups (40mg and 80mg orally. daily) for 12 weeks and monitored by drug tablet return</interventions>
    <comparator>routine dosage(80mg orally per 12 hours) for 12 weeks</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change in testosterone level with serum assay</outcome>
      <timepoint>three months post randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of participants with an improvement of LOH syndrome by Androgen Deficiency in the Aging Male questionnaire (ADAM) </outcome>
      <timepoint>three months post randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:
1. serum testerone level &lt;350ng/dl 
2.decreased sexual desire
3. erection dysfunctiond

participants  with all  the 3 criteria together should be eligible


</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.abnormal PSA or prostate cancer
2.hematocrit&gt;45%
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>12/02/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/12/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>shanghai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>zhou tie</primarysponsorname>
    <primarysponsoraddress>shanghai changhai road 168#, shanghai changhai hospital., shanghai, China, 200433</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>unfunded</fundingname>
      <fundingaddress>unfunded</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Overload dosage of Andriol Testocaps will not benefit the patients with LOH. In China, the patients with LOH were administrated with same dosage of Andriol Testocaps but lower BMI or weight compared with the westerns. Obviously, drug dosage heavily depends on the weight and BMI. Thus if Chinese patients are given similar dosage of Andriol Testocaps to the western patients, they may face the overdosage of Andriol Testocaps. In this study, we investigate the appropriate dosage of Andriol Testocaps for Chinese patients with LOH.   </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>changhai hospital ethics committee</ethicname>
      <ethicaddress>shanghai changhai road 168#, shanghai changhai hospital., shanghai, China, 200433</ethicaddress>
      <ethicapprovaldate>12/10/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>2/09/2015</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>zhou tie</name>
      <address>shanghai changhai road 168#, shanghai changhai hospital., shanghai, China, 200433</address>
      <phone>+8613918360523</phone>
      <fax />
      <email>wenzhoutie80@yahoo.com</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>zhou tie</name>
      <address>shanghai changhai road 168#, shanghai changhai hospital., shanghai, China, 200433</address>
      <phone>+8613918360523</phone>
      <fax />
      <email>wenzhoutie80@yahoo.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>zhou tie</name>
      <address>shanghai changhai road 168#, shanghai changhai hospital., shanghai, China, 200433</address>
      <phone>+8613918360523</phone>
      <fax />
      <email>wenzhoutie80@yahoo.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>